Paclitaxel (Phyxol) and Cisplatin as First-line Chemotherapy for Metastatic Breast Cancer

NCT ID: NCT00154882

Last Updated: 2010-01-21

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 43 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2003-09-30
• Study Completion Date: 2007-07-31

Brief Summary

The primary endpoint of this phase II trial is the objective response rate of the stage I (low-dose) regimen. The secondary endpoints include treatment-related toxicity, the change in quality of life, progression free survival and overall survival.

Detailed Description

Breast cancer is one of the leading causes of cancer death for women in Taiwan. We have recently demonstrated that combination of paclitaxel and cisplatin, at conventional doses, is highly effective in the treatment of breast cancer. However, the acute and cumulative toxicities of paclitaxel have been troublesome to a significant portion of the patients. Several lines of evidence suggested that weekly paclitaxel, at a much lower dose range of 40 to 50 mg/m2 per week, may be as effective as that of the conventional doses of paclitaxel (80 to 90 mg/m2 per week) for patients with metastatic ovarian and lung cancers. The low-dose regimen of paclitaxel may significantly improve the compliance of the patients. This open-label phase II trial is designed to test this hypothesis.

Conditions

Breast Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

A

Group Type: EXPERIMENTAL

Paclitaxel (Phyxol) , Cisplatin

Intervention Type: DRUG

Interventions

Paclitaxel (Phyxol) , Cisplatin

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Women with histologically proven breast cancer and clinical evidence of distant metastasis

2. The index lesions should be at least 20 mm × 20 mm in size

3. Age must be older than 18 and younger than 75 year-old

4. Karnofsky performance status > 70%

5. Adequate bone marrow reserves, defined as white blood cell (WBC) > 4,000, absolute neutrophil count (ANC) > 1,500, platelet > 100,000

6. Liver transaminases < 3 times upper normal limit if no liver metastasis and 5 times upper normal limit if liver metastasis is present; total bilirubin < 2 mg/dl; serum creatinine < 1.5 mg/dl

7. No prior chemotherapy for metastatic disease. Previous chemotherapy as adjuvant treatment is acceptable, if the adjuvant chemotherapy has been completed at least 6 months before entry into in this study

8. If the patients have received hormonal therapy for metastatic disease, there must be definite evidence of disease progression under the hormonal therapy, and hormonal therapy should be discontinued before entry into this study

9. Previous or concurrent radiotherapy is acceptable if the area of radiation does not involve the site of the index tumor lesions

10. Patients of childbearing age should have effective contraception during the study period

11. All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional guidelines.

Exclusion Criteria

1. Patients who are receiving concurrent hormonal or cytotoxic therapy or other experimental therapy. Concurrent therapy with other biological agents, such as Trastuzumab (Herceptin), is not allowed

2. Patients who refuse port-A catheter implantation

3. Patients who have received taxane (paclitaxel or docetaxel) or cisplatin as adjuvant chemotherapy

4. Patients with brain or leptomeningeal metastases

5. Patients who have significant cardiac arrhythmia or acute myocardial infarction within 6 months before entry

6. Patients who have major systemic diseases that the attending physicians considered inappropriate for systemic chemotherapy

7. Life expectancy less than 2 months

8. Pregnant or nursing patients may not participate. Patients with reproductive potential may not participate unless they have agreed to use an effective contraceptive method

9. No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancers, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any cancer from which the patient has been disease-free for 5 years

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

National Taiwan University Hospital

OTHER

Sponsor Role: lead

Principal Investigators

Yen-Shen Lu, M.D.

Role: PRINCIPAL_INVESTIGATOR

Department of Oncology , National Taiwan University Hospital

Locations

Department of Oncology , National Taiwan University Hospital

Taipei, , Taiwan

Site Status: RECRUITING

Countries

Taiwan

Central Contacts

Chiun Hsu, M.D., Ph.D.

Role: CONTACT

chiunhsu@ha.mc.ntu.edu.tw

886-2-23123456 ext. 7009

Yen-Shen Lu, M.D.

Role: CONTACT

yslu@ha.mc.ntu.edu.tw

886-2-23123456 ext. 7009

Facility Contacts

Yen-Shen Lu, M.D.

Role: primary

yslu@ha.mc.ntu.edu.tw

886-2-23123456 ext. 7009

Other Identifiers

920705

Identifier Type: -

Identifier Source: org_study_id